Similar articles

• Normocholesterolaemic dysslipidaemia: is there a role for fibrates?

  Hamilton-Craig I. Hamilton-Craig I. Med J Aust. 2001 Jun 4;174(11):610; author reply 611. doi: 10.5694/j.1326-5377.2001.tb143459.x. Med J Aust. 2001. PMID: 11453341 No abstract available.
• Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.

  Tikkanen MJ, Laakso M, Ilmonen M, Helve E, Kaarsalo E, Kilkki E, Saltevo J. Tikkanen MJ, et al. Diabetes Care. 1998 Apr;21(4):477-81. doi: 10.2337/diacare.21.4.477. Diabetes Care. 1998. PMID: 9571327 Clinical Trial.
• Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.

  Hutchesson AC, Moran A, Jones AF. Hutchesson AC, et al. J Clin Pharm Ther. 1994 Dec;19(6):387-9. doi: 10.1111/j.1365-2710.1994.tb00698.x. J Clin Pharm Ther. 1994. PMID: 7876371
• Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.

  Milionis HJ, Elisaf MS, Mikhailidis DP. Milionis HJ, et al. Curr Med Res Opin. 2000;16(1):21-32. doi: 10.1185/0300799009117004. Curr Med Res Opin. 2000. PMID: 16422031 Review.
• [Gemfibrozil: new aspects in clinical use].

  Tada N. Tada N. Nihon Rinsho. 2001 Mar;59 Suppl 3:625-30. Nihon Rinsho. 2001. PMID: 11347143 Review. Japanese. No abstract available.